Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | MRGPRX1 | Q96LB2 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | FADS1 | O60427 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.43 |
| ▸ | NOS2 | P35228 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1809103 | 0.90 | MRGPRX1 (0.49) | RECQLMRGPRX1MAPTLMNAFADS1 | |
| SCHEMBL6953541 | 0.87 | RECQL (0.60) | RECQLMRGPRX1MAPTLMNAUSP2 | |
| SCHEMBL12165544 | 0.81 | MRGPRX1 (0.51) | MRGPRX1MAPTLMNAUSP2MEN1 | |
| SCHEMBL2704610 | 0.78 | RECQL (0.58) | RECQLFADS1NPC1RAB9ATAS1R3 | |
| SCHEMBL2705343 | 0.77 | RECQL (0.59) | RECQLFADS1KMT2ANOS2SMN1; SMN2 | |
| SCHEMBL4124299 | 0.77 | RECQL (0.50) | RECQLMAPTLMNAUSP2MEN1 | |
| SCHEMBL5528744 | 0.76 | RECQL (0.60) | RECQLMAPTLMNAFADS1USP2 | |
| SCHEMBL10661181 | 0.76 | MAPT (0.44) | MRGPRX1MAPTLMNATP53ALOX15 | |
| SCHEMBL11314652 | 0.75 | TSHR (0.51) | MRGPRX1MAPTLMNAUSP2MEN1 | |
| SCHEMBL2705425 | 0.74 | RECQL (0.65) | RECQLMAPTLMNAALOX15TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2493305-B1 | 2-AMINOINDOLE COMPOUNDS AND METHODS FOR THE TREATMENT OF MALARIA | GENZYME CORP (US) | 2015-03-25 | — | — | EP | disclosed |
| US-8980926-B2 | 2-aminoindole compounds and methods for the treatment of malaria | GENZYME CORPORATION (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980926-B2 | 2-aminoindole compounds and methods for the treatment of malaria | GENZYME CORPORATION (US) | 2015-03-17 | — | — | US | disclosed |
| US-20120232063-A1 | 2-Aminoindole Compounds And Methods For The Treatment Of Malaria | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2012-09-13 | — | — | US | disclosed |
| US-20120232063-A1 | 2-Aminoindole Compounds And Methods For The Treatment Of Malaria | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2012-09-13 | — | — | US | disclosed |
| WO-2011053697-A1 | 2-AMINOINDOLE COMPOUNDS AND METHODS FOR THE TREATMENT OF MALARIA | GENZYME CORPORATION (US) | 2011-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232063-A1 | 2-Aminoindole Compounds And Methods For The Treatment Of Malaria | PNMT, AADAT, INMT | RECQL 957/4885MRGPRX1 924/4885MAPT 621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.